These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1053 related articles for article (PubMed ID: 29516506)

  • 61. Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma.
    Reiniger L; Téglási V; Pipek O; Rojkó L; Glasz T; Vágvölgyi A; Kovalszky I; Gyulai M; Lohinai Z; Rásó E; Tímár J; Döme B; Szállási Z; Moldvay J
    Acta Oncol; 2019 Aug; 58(8):1087-1094. PubMed ID: 31002007
    [No Abstract]   [Full Text] [Related]  

  • 62. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.
    Ota K; Azuma K; Kawahara A; Hattori S; Iwama E; Tanizaki J; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
    Clin Cancer Res; 2015 Sep; 21(17):4014-21. PubMed ID: 26019170
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer.
    Zuo HX; Jin Y; Wang Z; Li MY; Zhang ZH; Wang JY; Xing Y; Ri MH; Jin CH; Xu GH; Piao LX; Ma J; Jin X
    J Ethnopharmacol; 2020 Jul; 257():112835. PubMed ID: 32278762
    [TBL] [Abstract][Full Text] [Related]  

  • 64. PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation.
    Almozyan S; Colak D; Mansour F; Alaiya A; Al-Harazi O; Qattan A; Al-Mohanna F; Al-Alwan M; Ghebeh H
    Int J Cancer; 2017 Oct; 141(7):1402-1412. PubMed ID: 28614911
    [TBL] [Abstract][Full Text] [Related]  

  • 65. MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell Function.
    Ahn HK; Kim S; Kwon D; Koh J; Kim YA; Kim K; Chung DH; Jeon YK
    Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31480591
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Combined cryoablation and PD-1 inhibitor synergistically enhance antitumor immune responses in Lewis lung adenocarcinoma mice via the PI3K/AKT/mTOR pathway.
    Liu Q; Chen X; Qi M; Li Y; Chen W; Zhang C; Wang J; Han Z; Zhang C
    Biochim Biophys Acta Mol Basis Dis; 2024 Oct; 1870(7):167262. PubMed ID: 38815768
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Microwave ablation combined with PD-L1 blockade synergistically promotes Cxcl9-mediated antitumor immunity.
    He N; Huang H; Wu S; Ji W; Tai Y; Gao R; Liu Y; Liu Y; Chen L; Zhu D; Zheng X; Jiang J
    Cancer Sci; 2024 Jul; 115(7):2196-2208. PubMed ID: 38655660
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [IFN-γ induces overexpression of PD-L1 and epithelialmesenchymal transformation of breast cancer cells through activating ERK/Jak2-STAT signaling pathways].
    Yan Y; Zhao C; Yang R; Zhou T; Xu N
    Sheng Wu Gong Cheng Xue Bao; 2018 Dec; 34(12):2007-2015. PubMed ID: 30584711
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines.
    Yang L; Huang F; Mei J; Wang X; Zhang Q; Wang H; Xi M; You Z
    Int J Gynecol Cancer; 2017 Feb; 27(2):196-205. PubMed ID: 27870715
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dysregulation of the IFN-γ-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia.
    Kulling PM; Olson KC; Hamele CE; Toro MF; Tan SF; Feith DJ; Loughran TP
    PLoS One; 2018; 13(2):e0193429. PubMed ID: 29474442
    [TBL] [Abstract][Full Text] [Related]  

  • 71. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
    Thiem A; Hesbacher S; Kneitz H; di Primio T; Heppt MV; Hermanns HM; Goebeler M; Meierjohann S; Houben R; Schrama D
    J Exp Clin Cancer Res; 2019 Sep; 38(1):397. PubMed ID: 31506076
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
    Chen J; Jiang CC; Jin L; Zhang XD
    Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
    Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
    Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 75. In Situ PD-L1 Expression in Oral Squamous Cell Carcinoma Is Induced by Heterogeneous Mechanisms among Patients.
    Kondo Y; Suzuki S; Ono S; Goto M; Miyabe S; Ogawa T; Tsuchida H; Ito H; Takahara T; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456895
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
    Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
    FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells.
    Alsuliman A; Colak D; Al-Harazi O; Fitwi H; Tulbah A; Al-Tweigeri T; Al-Alwan M; Ghebeh H
    Mol Cancer; 2015 Aug; 14():149. PubMed ID: 26245467
    [TBL] [Abstract][Full Text] [Related]  

  • 78. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.
    Yoneshima Y; Ijichi K; Anai S; Ota K; Otsubo K; Iwama E; Tanaka K; Oda Y; Nakanishi Y; Okamoto I
    Lung Cancer; 2018 Apr; 118():36-40. PubMed ID: 29572000
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Interleukin-6 inhibition of peroxisome proliferator-activated receptor alpha expression is mediated by JAK2- and PI3K-induced STAT1/3 in HepG2 hepatocyte cells.
    Chew GS; Myers S; Shu-Chien AC; Muhammad TS
    Mol Cell Biochem; 2014 Mar; 388(1-2):25-37. PubMed ID: 24242046
    [TBL] [Abstract][Full Text] [Related]  

  • 80. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
    Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
    Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.